

## Combination therapeutics in complex diseases

Bing He<sup>a, b</sup>, Cheng Lu<sup>a, b, c</sup>, Guang Zheng<sup>a, b</sup>, Xiaojuan He<sup>a, b, c</sup>, Maolin Wang<sup>a, b</sup>, Gao Chen<sup>a, b</sup>,  
Ge Zhang<sup>a, b, \*</sup>, Aiping Lu<sup>a, b, c, \*</sup>

<sup>a</sup> Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine,  
Hong Kong Baptist University, Hong Kong, China

<sup>b</sup> Institute of Integrated Biomedicine & Translational Science, HKBU Shenzhen Research Institute and Continuing Education,  
Shenzhen, China

<sup>c</sup> Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China

Received: January 9, 2016; Accepted: June 16, 2016

- Introduction
- Combination therapeutics and drugs with multiple targets
- Drug selection for combination therapeutics
- Drug combinations are much more than synergistic

- The development of combination therapeutics in cell lines and animal models
- The development of combination therapeutics using computational approaches
- Conclusions

### Abstract

The biological redundancies in molecular networks of complex diseases limit the efficacy of many single drug therapies. Combination therapeutics, as a common therapeutic method, involve pharmacological intervention using several drugs that interact with multiple targets in the molecular networks of diseases and may achieve better efficacy and/or less toxicity than monotherapy in practice. The development of combination therapeutics is complicated by several critical issues, including identifying multiple targets, targeting strategies and the drug combination. This review summarizes the current achievements in combination therapeutics, with a particular emphasis on the efforts to develop combination therapeutics for complex diseases.

**Keywords:** combination therapeutics • complex diseases • molecular network

### Introduction

Living systems in the human body are interconnected networks of molecular components [1]. Multiple complex molecular networks are involved in the mechanisms of many common diseases, especially in complex diseases (*e.g.*, arthritis, diabetes, heart disease, cancer and asthma) [2–6]. The complexity of these diseases limits the efficacy of commonly used single molecular drug therapeutics, which has led to a critical situation in new drug discovery in recent years [7]. The strategy of combination therapeutics has been revisited with the hope of addressing this issue [8].

The number of studies investigating combination therapeutics is increasing annually (Fig. 1). Moreover, some drug combinations have entered clinical trials for the treatment of complex diseases (Table 1).


This review will summarize the current achievements in combination therapeutics in complex diseases, with a particular focus on the computational strategy for drug combination.

### Combination therapeutics and drugs with multiple targets

Combination therapeutics are concerted pharmacological interventions consisting of several drugs that interact with multiple targets. The combination of drugs may be antagonistic, additive or synergistic

\*Correspondence to: Dr. Ge ZHANG, M.D.  
E-mail: zhangge@hkbu.edu.hk

Dr. Aiping LU, M.D., Ph.D.  
E-mail: aipinglu@hkbu.edu.hk



**Fig. 1** Statistics of combination therapeutic studies by year. The data were obtained from the PubMed database.

if the combined effect is less than, equal to or greater than the sum of the individual drugs, respectively [9]. Synergistic drug combinations have numerous advantages over monotherapy, including increased efficacy, decreased dosage with equal efficacy, reduced side effects and reduced drug resistance [10]. These advantages are mainly due to the targeting of multiple molecular networks in the human body. Complex molecular networks are involved in various biological functions of the human body. For example, bone homeostasis, the process of creating new bone and removing old bone [11], has been found to be regulated by the WNT protein signalling pathway [12], the Notch signalling pathway [13], the RANK signalling pathway [14] and the bone morphogenetic protein (BMP) signalling pathway [15].

Moreover, the molecular networks in the human body are also likely to be modulated by redundant pathways, which can compensate for one another if either one is inhibited. For example, BMP induces transcriptional activation mediated by SMAD1, SMAD5 and SMAD8, which functionally compensate for each other in various biological processes such as bone formation [16], trigeminal ganglia subtype specification [17] and stem cell differentiation [18]. Such pathways are therefore optimally inhibited by multiple drugs that block all SMAD1/5/8 pathways, which ensures that the other pathways do not partially or completely compensate for the inhibition [16]. Blocking the upstream signal (for example, the BMP receptor in this case) would not be appropriate because although it could inhibit all SMAD1/

**Table 1** Recent clinical trials of combination therapeutics used for the treatment of complex diseases. We obtained data from articles published in *Lancet* and *The New England Journal of Medicine* in the previous 3 years

Disease	Combination therapeutics
Hypertension	Nebivolol + valsartan [33]
Pyelonephritis	Ceftolozane + tazobactam [98]
Membranous nephropathy	Prednisolone + chlorambucil [99]
Diabetes	Dulaglutide + lispro [100]
Rheumatoid arthritis	Adalimumab + methotrexate [101]; Tofacitinib + methotrexate [102]
Myeloma	Lenalidomide + dexamethasone+ carfilzomib [103]; Lenalidomide + dexamethasone [104, 105]
Colorectal cancer	Capecitabine + bevacizumab [106]; FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)+ bevacizumab [107]
Pancreatic cancer	Gemcitabine + nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) [108–110]
Chronic lymphocytic leukaemia	Obinutuzumab + chlorambucil [111]
B-cell lymphoma	Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone [112]
Breast cancer	Pertuzumab + trastuzumab + docetaxel [113]; Paclitaxel + trastuzumab [114]
Melanoma	Trametinib + dabrafenib [115, 116]; Nivolumab + Ipilimumab [117, 118]; Dabrafenib + trametinib [119]

5/8 pathways, it would also block other downstream BMP signalling pathways, which could potentially lead to undesirable effects.

In addition to combination therapeutics, one drug might also target multiple functions [19]. A drug that is designed to target multiple processes is an adjusted combination therapeutic in single drug form [20]. Multi-target drugs might overcome molecular heterogeneity within or between patients diagnosed with complex diseases, such as non-small-cell lung cancer [21], gastrointestinal stromal tumours [22] and pulmonary fibrosis [23], and would therefore have a better chance of successful clinical development, especially when biomarkers for patient selection are uncertain. However, such a multi-target drug might not be ideal for reasonable therapeutic strategies based on specific molecular profiles of diseases. Because these drugs are not well 'designed' to interact with a particular set of targets, they may not achieve optimal inhibition of the specific individual targets in a particular disease [24]. For example, during kinase inhibition, screening to detect the inhibitory activities of particular kinases of interest resulted in the identification of multi-targeted kinase inhibitors. However, additional kinases with structural similarities will be inhibited, potentially leading to additional toxicity because cumulative target and off-target inhibition has a broader, and perhaps less predictable, effect on cellular functions [24, 25]. For example, Sorafenib, a multi-target tyrosine kinase inhibitor with potent anti-angiogenic activity that is used to treat solid tumours, induces irreversible pancreatic atrophy in patients after long-term administration [26].

In contrast, the combination of more specific targeted drugs may be more suitable for therapeutics tailored to individual patients based on the specific molecular disease profiles [27]. Physicians might adjust the concentrations of drugs within a combination therapeutic to enhance targeted inhibition and to optimize synergy between drugs [28]. The toxicity of the combination might also be more predictable due to limited off-target effects [29].

## Drug selection for combination therapeutics

Currently, most of the drugs in combination therapeutics are chemosynthetic molecules. For example, Ser-Ap-Es<sup>®</sup>, which has been used for the treatment of hypertension since the 1950s, is a triple-chemical-drug combination that includes reserpine, apresoline and hydrochlorothiazide. Hypertension is a complex cardiovascular disease, and approximately 30% of the adult population in the United States suffers from this condition [30]. Law *et al.* have suggested that low-dose combinations from the five major classes of antihypertensive drugs (diuretics, beta-blockers, angiotensin-receptor blockers, calcium-channel blockers and angiotensin-converting enzyme inhibitors) are more effective for reducing blood pressure and associated with fewer side effects than monotherapy [31]. Taylor and Ragbir evaluated some triple-drug combinations and showed that they were well-tolerated with a low incidence of side effects [32]. Recently, a fixed-dose combination of a vasodilating  $\beta$ -blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) was shown to be an effective and well-tolerated treatment option for patients with hypertension

in an 8-week, phase 3, multi-centre, randomized, double-blind, placebo-controlled, parallel-group trial [33].

Bioengineering products are becoming another important source of drugs for combination therapeutics. Monoclonal antibodies are the most common form of this type of drug [34]. For example, trastuzumab, a monoclonal antibody that interferes with the HER2 receptor, has been used in combination with cisplatin to inhibit the progression of gastric cancer [35]. Cisplatin induces DNA damage and apoptosis, which may be attenuated by DNA repair systems [36]. Trastuzumab suppresses the DNA repair pathway and the PI3K-AKT pathway [37] to increase cellular apoptosis [38]. The combination of ramucirumab, a human monoclonal antibody against VEGFR2, and paclitaxel significantly increased the overall survival of gastric cancer patients in a randomized, placebo-controlled, double-blind, phase 3 trial in 27 countries in North and South America, Europe, Asia and Australia [39].

Herbs have been widely used in eastern Asia for thousands of years. Herbal compounds would be good candidates for combination therapeutics. There are already several successful cases examining this theory. Paclitaxel, a drug developed from a compound isolated from the bark of the pacific yew tree, *Taxus brevifolia*, is now widely used in combination therapeutics for cancer treatment. The combination of paclitaxel and bortezomib, a proteasome inhibitor that modulates apoptosis and the cell cycle by disrupting protein degradation, improves overall survival of non-small cell lung cancer patients [40]. Total glucosides of peony, active compounds extracted from the roots of the herb *Paeonia lactiflora* Pall, reduce hepatotoxicity in combination with leflunomide and methotrexate in patients with active rheumatoid arthritis [41]. In China, the herb *Artemisia annua* is used to treat fever and malaria. In 1971, artemisinin was isolated from the leafy portions of the *A. annua* plant and found to be effective for the treatment of malaria [42]. Artemisinin-combination therapy is now recommended as a first-line treatment for falciparum malaria worldwide, and fixed-dose combinations are preferred by the WHO. In addition, some combinations of herbal compounds are in preclinical phases. Deng *et al.* have indicated that the combination of salvianolic acid B and ginsenoside Rg1, which are derived from roots of *Salvia miltiorrhiza* and *Panax notoginseng*, respectively, improve the viability of cardiac myocytes in rats with ischaemia/reperfusion injury [43]. Zhang *et al.* have found that tetramethylpyrazine, a compound isolated from *Ligusticum wallichii* Franchet, ameliorates oxidative organ injury associated with methotrexate treatment in patients with rheumatoid arthritis [44]. These examples illustrate the possibility of utilizing herbal compounds in combination therapeutics. Therefore, herb might be a rich resource for the discovery of combination therapeutics.

## Drug combinations are much more than synergistic

In the clinic, physicians often face the following pragmatic question: should I use a second drug as an add-on instead of using more of the first drug? In the case of complex diseases, the answer will often be that an increased amount of the first drug cannot produce the effect that is desired by the physician, but this effect can be achieved with

combination treatment [28]. Moreover, in some cases, the addition of more of the same drug will induce unacceptable negative influence. For example, when the dosage of the first drug is slightly under the threshold of toxicity, even a small dosage increase may be unacceptable [45]. Therefore, combining the first medication with a second drug that produces non-overlapping toxicities may be beneficial, even when the combined effects on efficacy are only Loewe additive [34, 35], which refers to a model of drug combination and will be introduced in the next paragraph. Ultimately, the ideal design of combination therapeutics must reflect the requirement of the physician that, when drugs are used in combination, an extra benefit is observed that cannot be achieved by using the constituent drugs alone. The extra benefit is mainly derived from the synergistic effects of the combined drugs (Fig. 2A).

The word synergy is derived from the Greek words *sunergia*, which means 'cooperation', and *sunergos*, which means 'working together' [19]. Modern pharmacology has embraced this concept to emphasize the idea that a synergistic combination provides greater effects than those predicted by simply adding the effects of individual parts [10]. Numerous investigators have attempted to provide a framework to calculate the additive effects among constituents [46–48]. Among these works, the Loewe additivity [49, 50] and Bliss independence [46, 51] models are two of the most useful frameworks of synergy.

The Loewe additivity model assumes that two drugs act through similar mechanisms. Equipotent dose ratios determine the effects of each drug and their combination. According to this model, the combined activity level,  $L_{x,y}$ , of the two drugs X and Y at the concentrations,  $C_x$  and  $C_y$ , satisfies the equation,  $\frac{C-x}{C(L_x=L_{x,y})} + \frac{C-y}{C(L_y=L_{x,y})} = 1$ . In this equation,  $C_x$  and  $C_y$  are the single-agent concentrations for X and Y, which individually produce an activity of  $L_{x,y}$ .

The Bliss independence model assumes that two drugs act through independent mechanisms. The combination effect in this model is represented as the union of two probabilistically independent events [46]. According to this model, the combined activity,  $L_{x,y}$ , of two compounds X and Y at the concentrations,  $C_x$  and  $C_y$ , satisfies the equation,  $L_{x,y} = L_x + L_y - L_x L_y$ . In this equation,  $L_x$  and  $L_y$  are the single-agent activity levels at concentrations  $C_x$  and  $C_y$ .

These two models produce different outcome, and only the Loewe additivity model correctly predicts the cases in which the two compounds are actually the same constituent. However, the debate continues over which model performs better in cases involving noisy clinical data and uncertain therapeutic mechanisms [46, 52, 53].

Nonetheless, synergy is not the only reason for drug combinations. Sometimes the combination of antagonistic drugs may also be beneficial (Fig. 2B). In fact, the combination can have two conflicting effects: it may reduce the evolution of drug resistance because it cures the disease faster, thereby limiting the time window available for drug resistant mutations to accumulate, but it may also increase the selective advantage of drug-resistant mutants [54]. If a strong

resource competition is present, the latter effect will dominate [54]. In fact, under these conditions, antagonistic drug combinations, which are less potent than the sum of the components, have been shown to limit the evolution of drug resistance [55–57]. The advantage of antagonistic combinations over synergistic combinations is the result of a reduced fitness gain of drug-resistant mutants (Fig. 2B) [55–57].

In addition to synergistic and antagonistic drug interactions, collateral responses among drugs also play a role in combination therapeutics (Fig. 2C) [58]. Collateral response (sensitivity or resistance), also known as cross-resistance, is the ability of one drug to increase or decrease sensitivity to another drug (Fig. 2C). The study of collateral susceptibility changes started in the early 1950s [59] and has been reported for many different drugs in subsequent years [60–62]. Recently, Munck *et al.* studied the development of resistance against drug combinations by investigating collateral responses to component drugs [58]. The authors provided a framework for the rational selection of drug combinations that limit resistance evolution using *Escherichia coli*.


In general, the benefits of combination therapeutics mainly result from synergistic effects. Antagonistic effects and collateral responses may also produce extra benefits by decreasing drug resistance. Therefore, combination therapeutics can be more complicated than simply taking different drugs together. To investigate the rationale of combination therapeutics, preclinical combinational studies should be performed prior to the initiation of clinical trials.

## The development of combination therapeutics in cell lines and animal models

A common strategy to investigate combination therapeutics prior to the initiation of clinical trials is through the use of cell lines and animal models. These models provide important insights into the mechanisms of action and interactions between drugs, which are important in the preparation for clinical trials [63]. For example, DiCosimo *et al.* estimated the efficacy of combined ridaforolimus and dalotuzumab for the treatment of breast cancer in human cell lines and mouse models, and the results of those studies led to the initiation of a phase I clinical trial [64]. In fact, preclinical studies make up the majority of studies investigating (Fig. 1) and play an essential role in the development of combination therapeutics [65]. In general, preclinical studies of combination therapeutics rapidly assess the synergy of combined drugs and explore physical interactions among them. They also evaluate anti-disease activity, mechanisms of action and additional factors, such as the effects of the drugs on their targets and their pharmacokinetics [66].

---

**Fig. 2** The three drug combination patterns in combination therapeutics. (A) The synergy drug combination improves therapeutic effects compared with the single drug treatment. (B) During long-term treatment, drug resistance increases with time. The antagonist drug combination limits the evolution of drug resistance and results in improved therapeutic effects. (C) After long-term drug A treatment, collateral responses increase resistance to drug A and decrease resistance to drug B. Therefore, the addition of drug B to treatment will improve the therapeutic effect.





However, despite the large number of preclinical combination therapeutics studies, the number of successful clinical trials is limited (Fig. 1). It appears that the success or failure of clinical trials examining combination therapeutics can hardly be predicted on the basis of published preclinical data [67]. The lack of concordance between preclinical studies and clinical trials is not surprising. Preclinical studies are limited in experimental design and animal models [63]. In experiments that are designed to evaluate the activity of combined drugs, assessments are performed with limited consideration of how the drugs are likely to function in patients [63]. Such evaluations can provide insights into the mechanisms responsible for anti-disease actions and the interactions between the drugs within the parameters of the experiment. However, interpretation of the evaluations and the subsequent design of clinical trials for complex diseases must encompass numerous variables that might exceed the designed parameters of preclinical experiments, such as drug dose, scheduling and route of administration [68].

Even when researchers have thoroughly designed all of the parameters of preclinical experiments for combination therapeutics, the inherent limitations of animal models continue to weaken the correlation between laboratory and clinical outcome. The most important limitation is that the drug targets are host components and are therefore of animal, not human, origin [65]. In other words, a drug that works well in an animal model may not necessarily work in humans. After assessing the correlation between cancer animal models and the clinical activity of single cytotoxic drugs, previous studies have suggested that the predictive value of cytotoxic drugs in murine models is limited [69, 70]. Limiting experimentation to a few animal models cannot reflect the diversity of complex human diseases and may explain the failure of clinical trials based on preclinical data [67]. A detailed understanding of human biology may enable the design of *a priori* combination therapeutics to increase the success rate of clinical trials. A growing number of scientists in the field of therapeutic discovery are attempting to understand biology and disease using computational approaches [71].

## The development of combination therapeutics using computational approaches

Computational approaches, particularly those integrating data analysis and artificial intelligence, may assist in the design of combination therapeutics by generating drug–target interaction networks and predicting drug combinations. Computational assistant construction of drug–target interaction networks mainly refer to computational algorithms and programs to reveal molecular mechanisms and connections between drugs and targets in a dynamic network [72]. These methods can be used to explore the therapeutic mechanisms underlying drug treatment at the molecular level [73]. Common methods of this type include knowledge- and ligand-based approaches.

Knowledge-based approaches are high-throughput computational methods of artificial intelligence that enable computers to learn from

the available knowledge, including drug chemistry and structural information, as well as drug–target networks, to predict new knowledge, such as new drug indications, targets and drug–target interactions [74]. These approaches can be classified into unsupervised and supervised methods [75]. The unsupervised methods extract and predict patterns and interactions based on a series of input variables. The commonly used unsupervised methods include clustering, data compression and outlier detection methods such as principal-component-based methods [76]. For example, Guimera *et al.* studied novel drug–drug interactions using a large-scale unsupervised method that deals with various types of data to accurately predict adverse, synergistic and antagonistic drug interactions [77]. Kissa *et al.* examined drug–gene associations and assisted in drug repositioning with a fully corpus-based unsupervised method that utilizes the available knowledge [78]. The supervised methods divide the data into training and validation datasets, and they finalize a robust model that can be used to predict the binding probability between drugs and targets [79]. The most widely used supervised methods are the Bayesian model [80], the support vector machine [81] and the decision tree [82]. These methods can be combined if appropriate. For example, Kim *et al.* predicted drug–target interactions by applying two machine learning approaches, a support vector machine and a kernel-based L1-norm regularized logistic regression, to evaluate drug–drug interaction data [83].

Ligands are small molecules that bind to a site on a target protein to alter the biological functions of the protein. Ligand-based approaches predict drug–target interactions by means of chemical or structural ligand similarities, with the basic assumption that similar ligands tend to bind to similar targets [84]. Ligand-based approaches are highly dependent on the availability of chemical and structural information on targets, from either wet experiments or numerical simulations [85, 86]. The similarity ensemble approach [87], the pharmacophore model [88], docking [89] and quantitative structure–activity relationships [90] are commonly used methods. Based on these types of methods, Yco *et al.* identified sepiapterin reductase as a new therapeutic target for the treatment of human neuroblastoma [91].

Knowledge- and ligand-based approaches are often combined to achieve better results. Afzal *et al.* combined multiple methods to construct drug–target predictions and obtained more applicable results [92]. These computational approaches accelerate the acquisition of drug–target data. The accumulation of these data, once again, promotes novel predictions of drugs targets [93].

In addition to accelerating the accumulation of drug targets, computational approaches directly predict new combination therapeutics. Bansal *et al.* assessed 32 computational approaches and found that the computational prediction of drug combination activity is possible [94]. The prediction of new combination therapeutics should include network pharmacology that encompasses systems biology, network analysis, connectivity, redundancy and pleiotropy [95]. Gu *et al.* predicted a drug combination in the context of the pathway network of the biological process [96]. The computational approach may become an important complement to traditional preclinical studies. It is possible that computational approaches will be used to identify promising combinations that can be tested *in vitro* to further determine the combinations, which would be advantageous compared with random

combination screening *in vitro*. This method may even replace *in vitro* screening in cell lines in the future, but *in vivo* efficacy testing would be still required. Large and complex biological data and multiple computational methods are often used in studies focused on the prediction of combination therapeutics [97]. With the accumulation of chemical, biological, 'omics' data and the advancement of artificial intelligence, computational approaches will acquire a more prominent role in the development of combination therapeutics for complex diseases.

## Conclusions

The use of combination therapeutics is an appropriate approach to address the complexity of human diseases. The advantages of combination therapeutics are mainly due to the ability of combination products to act on multiple targets. Chemical drugs, biological drugs and drugs from natural products are widely used in combination therapeutics. Drug interactions, including synergistic and antagonistic drug interactions, as well as collateral responses, might influence the therapeutic actions of drug combinations. Preclinical studies in cell and animal models have been performed to evaluate the effects of drug combinations. However, subsequent successful clinical trials of drug combinations are limited, potentially because the limited experimental conditions in preclinical studies cannot reflect the diversity of

complex diseases. Computational approaches can complement traditional preclinical studies. The use of computational approaches not only facilitates an understanding of drug interactions, but it also promotes the discovery of new combination therapeutics. Computational approaches might help to define the number of candidate combinations for further *in vitro* and *in vivo* investigations. In future, the accumulation of multiple types of human 'omics' data, including genomics, transcriptomics, proteomics and metabolome, among others, will deepen our understanding of complex diseases and promote the computational discovery of combination therapeutics.

## Acknowledgements

This work is supported by the Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist University (RC-IRMS/12-13/02), the Research Committee of Hong Kong Baptist University (33-12-903), the Hong Kong Baptist University Strategic Development Fund (SDF13-1209-P01), the National Science and Technology Major Projects for 'major New Drugs Innovation and Development' (2013ZX09301307) and the Hospital Authority (HA 820/126/19/19/14/6/12/1).

## Conflict of interest

The authors declare that there are no conflicts of interest.

## References

1. Gerstein MB, Kundaje A, Hariharan M, *et al*. Architecture of the human regulatory network derived from ENCODE data. *Nature*. 2012; 489: 91–100.
2. Okada Y, Wu D, Trynka G, *et al*. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature*. 2014; 506: 376–81.
3. DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in multi-Ethnic Samples (T2D-GENES) Consortium, Mahajan A, Go MJ, Zhang W, *et al*. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat Genet*. 2014; 46: 234–44.
4. Arking DE, Pulit SL, Crotti L, *et al*. Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. *Nat Genet*. 2014; 46: 826–36.
5. Lin DC, Meng X, Hazawa M, *et al*. The genomic landscape of nasopharyngeal carcinoma. *Nat Genet*. 2014; 46: 866–71.
6. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. *Immunol Rev*. 2011; 242: 10–30.
7. Scannell JW, Blanckley A, Boldon H, *et al*. Diagnosing the decline in pharmaceutical R&D efficiency. *Nat Rev Drug Discov*. 2012; 11: 191–200.
8. Podolsky SH, Greene JA. Combination drugs—hype, harm, and hope. *N Engl J Med*. 2011; 365: 488–91.
9. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol Rev*. 2006; 58: 621–81.
10. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. *Drug Discov Today*. 2007; 12: 34–42.
11. Rodan GA. Bone homeostasis. *Proc Natl Acad Sci USA*. 1998; 95: 13361–2.
12. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med*. 2013; 19: 179–92.
13. Engin F, Yao Z, Yang T, *et al*. Dimorphic effects of Notch signaling in bone homeostasis. *Nat Med*. 2008; 14: 299–305.
14. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature*. 2003; 423: 337–42.
15. Yamashita M, Ying SX, Zhang GM, *et al*. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. *Cell*. 2005; 121: 101–13.
16. Retting KN, Song B, Yoon BS, *et al*. BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. *Development*. 2009; 136: 1093–104.
17. Ji SJ, Jaffrey SR. Intra-axonal translation of SMAD1/5/8 mediates retrograde regulation of trigeminal ganglia subtype specification. *Neuron*. 2012; 74: 95–107.
18. Park ES, Woods DC, Tilly JL. Bone morphogenetic protein 4 promotes mammalian oogonial stem cell differentiation via

- Smad1/5/8 signaling. *Fertil Steril*. 2013; 100: 1468–75.
19. **Keith CT, Boris AA, Stockwell BR.** Multi-component therapeutics for networked systems. *Nat Rev Drug Discov*. 2005; 4: 71–8.
  20. **Pang MH, Kim Y, Jung KW, et al.** A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. *Drug Discov Today*. 2012; 17: 425–34.
  21. **Cataldo VD, Gibbons DL, Perez-Soler R, et al.** Treatment of non-small-cell lung cancer with erlotinib or gefitinib. *N Engl J Med*. 2011; 364: 947–55.
  22. **Maynard MA, Marino-Enriquez A, Fletcher JA, et al.** Thyroid hormone inactivation in gastrointestinal stromal tumors. *N Engl J Med*. 2014; 370: 1327–34.
  23. **Richeldi L, du Bois RM, Raghu G, et al.** Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014; 370: 2071–82.
  24. **Koeberle A, Werz O.** Multi-target approach for natural products in inflammation. *Drug Discov Today*. 2014; 19: 1871–82.
  25. **Force T, Kolaja KL.** Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. *Nat Rev Drug Discov*. 2011; 10: 111–26.
  26. **Hescot S, Vignaux O, Goldwasser F.** Pancreatic atrophy—a new late toxic effect of sorafenib. *N Engl J Med*. 2013; 369: 1475–6.
  27. **Greco F, Vicent MJ.** Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. *Adv Drug Deliv Rev*. 2009; 61: 1203–13.
  28. **Postow MA, Chesney J, Pavlick AC, et al.** Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med*. 2015; 372: 2006–17.
  29. **D'Angelo L, Piazza G, Pacilli A, et al.** A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells. *Carcinogenesis*. 2014; 35: 2314–20.
  30. **Roger VL, Go AS, Lloyd-Jones DM, et al.** Heart disease and stroke statistics—2012 update: a report from the American Heart Association. *Circulation*. 2012; 125: e2–220.
  31. **Law MR, Wald NJ, Morris JK, et al.** Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *BMJ*. 2003; 326: 1427.
  32. **Taylor AA, Ragbir S.** Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension. *Patient Prefer Adherence*. 2012; 6: 555–63.
  33. **Giles TD, Weber MA, Basile J, et al.** Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. *Lancet*. 2014; 383: 1889–98.
  34. **Dranitsaris G, Amir E, Dorward K.** Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. *Drugs*. 2011; 71: 1527–36.
  35. **Kim SY, Kim HP, Kim YJ, et al.** Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. *Int J Oncol*. 2008; 32: 89–95.
  36. **Siddik ZH.** Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene*. 2003; 22: 7265–79.
  37. **Le XF, Lammayot A, Gold D, et al.** Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. *J Biol Chem*. 2005; 280: 2092–104.
  38. **Lee S, Yang W, Lan KH, et al.** Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. *Cancer Res*. 2002; 62: 5703–10.
  39. **Wilke H, Muro K, Van Cutsem E, et al.** Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2014; 15: 1224–35.
  40. **Zhao Y, Foster NR, Meyers JP, et al.** A phase I/II study of bortezomib in combination with paclitaxel, carboplatin and concurrent thoracic radiation therapy for non-small cell lung cancer: NCCTG-N0321. *J Thorac Oncol*. 2014; 10: 172–80.
  41. **Chen Z, Li XP, Li ZJ, et al.** Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. *Int Immunopharmacol*. 2013; 15: 474–7.
  42. **Klayman DL.** Qinghaosu (artemisinin): an antimalarial drug from China. *Science*. 1985; 228: 1049–55.
  43. **Deng Y, Yang M, Xu F, et al.** Combined salvianolic acid B and ginsenoside Rg1 exerts cardioprotection against ischemia/reperfusion injury in rats. *PLoS ONE*. 2015; 10: e0135435.
  44. **Zhang B, Lu C, Bai M, et al.** Tetramethylpyrazine identified by network pharmacology approaches ameliorates methotrexate-induced oxidative organ injury. *J Ethnopharmacol*. 2015; 175: 638–47.
  45. **Klaassen CD.** *Casarett and Doull's Toxicology: the basic science of poisons*. New York: McGraw-Hill; 2013.
  46. **Greco WR, Bravo G, Parsons JC.** The search for synergy: a critical review from a response surface perspective. *Pharmacol Rev*. 1995; 47: 331–85.
  47. **Chou TC, Talalay P.** Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul*. 1984; 22: 27–55.
  48. **Groten JP, Feron VJ, Suhnel J.** Toxicology of simple and complex mixtures. *Trends Pharmacol Sci*. 2001; 22: 316–22.
  49. **Loewe S.** Die quantitation probleme der pharmakologie. *Ergebn Physiol*. 1928; 27: 47–187.
  50. **Loewe S.** The problem of synergism and antagonism of combined drugs. *Arzneimittelforschung*. 1953; 3: 285–90.
  51. **Bliss CI.** The calculation of microbial assays. *Bacteriol Rev*. 1956; 20: 243–58.
  52. **Martinez-Irujo JJ, Villahermosa ML, Mercapide J, et al.** Analysis of the combined effect of two linear inhibitors on a single enzyme. *Biochem J*. 1998; 329(Pt 3): 689–98.
  53. **Prichard MN, Shipman C Jr.** A three-dimensional model to analyze drug-drug interactions. *Antiviral Res*. 1990; 14: 181–205.
  54. **Torella JP, Chait R, Kishony R.** Optimal drug synergy in antimicrobial treatments. *PLoS Comput Biol*. 2010; 6: e1000796.
  55. **Chait R, Craney A, Kishony R.** Antibiotic interactions that select against resistance. *Nature*. 2007; 446: 668–71.
  56. **Hegreness M, Shores N, Damian D, et al.** Accelerated evolution of resistance in multidrug environments. *Proc Natl Acad Sci USA*. 2008; 105: 13977–81.
  57. **Michel JB, Yeh PJ, Chait R, et al.** Drug interactions modulate the potential for evolution of resistance. *Proc Natl Acad Sci USA*. 2008; 105: 14918–23.
  58. **Munck C, Gumpert HK, Wallin AI, et al.** Prediction of resistance development against drug combinations by collateral responses to component drugs. *Sci Transl Med*. 2014; 6: 262ra156.
  59. **Szybalski W, Bryson V.** Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of *Escherichia coli* to fifteen antibiotics. *J Bacteriol*. 1952; 64: 489–99.



60. **Chao L.** An unusual interaction between the target of nalidixic acid and novobiocin. *Nature*. 1978; 271: 385–6.
61. **Muller FL, Colla S, Aquilanti E, et al.** Passenger deletions generate therapeutic vulnerabilities in cancer. *Nature*. 2012; 488: 337–42.
62. **Deeks SG.** Treatment of antiretroviral-drug-resistant HIV-1 infection. *Lancet*. 2003; 362: 2002–11.
63. **Dahlin JL, Inglese J, Walters MA.** Mitigating risk in academic preclinical drug discovery. *Nat Rev Drug Discov*. 2015; 14: 279–94.
64. **DiCosimo S, Sathyanarayanan S, Bendell JC, et al.** Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial. *Clin Cancer Res*. 2014; 21: 49–59.
65. **Wendler A, Wehling M.** The translatability of animal models for clinical development: biomarkers and disease models. *Curr Opin Pharmacol*. 2010; 10: 601–6.
66. **Dancey JE, Chen HX.** Strategies for optimizing combinations of molecularly targeted anticancer agents. *Nat Rev Drug Discov*. 2006; 5: 649–59.
67. **Pusztai L, Hatzis C, Andre F.** Reproducibility of research and preclinical validation: problems and solutions. *Nat Rev Clin Oncol*. 2013; 10: 720–4.
68. **Lovering F, Bikker J, Humblet C.** Escape from flatland: increasing saturation as an approach to improving clinical success. *J Med Chem*. 2009; 52: 6752–6.
69. **Johnson JI, Decker S, Zaharevitz D, et al.** Relationships between drug activity in NCI preclinical *in vitro* and *in vivo* models and early clinical trials. *Br J Cancer*. 2001; 84: 1424–31.
70. **Voskoglou-Nomikos T, Pater JL, Seymour L.** Clinical predictive value of the *in vitro* cell line, human xenograft, and mouse allograft preclinical cancer models. *Clin Cancer Res*. 2003; 9: 4227–39.
71. **Thiele I, Swainston N, Fleming RM, et al.** A community-driven global reconstruction of human metabolism. *Nat Biotechnol*. 2013; 31: 419–25.
72. **Leung EL, Cao ZW, Jiang ZH, et al.** Network-based drug discovery by integrating systems biology and computational technologies. *Brief Bioinform*. 2013; 14: 491–505.
73. **Harrold JM, Ramanathan M, Mager DE.** Network-based approaches in drug discovery and early development. *Clin Pharmacol Ther*. 2013; 94: 651–8.
74. **Tang GW, Altman RB.** Knowledge-based fragment binding prediction. *PLoS Comput Biol*. 2014; 10: e1003589.
75. **Ding H, Takigawa I, Mamitsuka H, et al.** Similarity-based machine learning methods for predicting drug-target interactions: a brief review. *Brief Bioinform*. 2014; 15: 734–47.
76. **Strombergsson H, Kleywegt GJ.** A chemogenomics view on protein-ligand spaces. *BMC Bioinform*. 2009; 10 (Suppl. 6): S13.
77. **Guimera R, Sales-Pardo M.** A network inference method for large-scale unsupervised identification of novel drug-drug interactions. *PLoS Comput Biol*. 2013; 9: e1003374.
78. **Kissa M, Tsatsaronis G, Schroeder M.** Prediction of drug gene associations via ontological profile similarity with application to drug repositioning. *Methods*. 2015; 74: 71–82.
79. **Jensen LJ, Bateman A.** The rise and fall of supervised machine learning techniques. *Bioinformatics*. 2011; 27: 3331–2.
80. **Nigsch F, Bender A, Jenkins JL, et al.** Ligand-target prediction using Winnow and naive Bayesian algorithms and the implications of overall performance statistics. *J Chem Inf Model*. 2008; 48: 2313–25.
81. **Sugaya N.** Training based on ligand efficiency improves prediction of bioactivities of ligands and drug target proteins in a machine learning approach. *J Chem Inf Model*. 2013; 53: 2525–37.
82. **Han L, Wang Y, Bryant SH.** Developing and validating predictive decision tree models from mining chemical structural fingerprints and high-throughput screening data in PubChem. *BMC Bioinform*. 2008; 9: 401.
83. **Kim S, Jin D, Lee H.** Predicting drug-target interactions using drug-drug interactions. *PLoS ONE*. 2013; 8: e80129.
84. **Bender A, Glen RC.** Molecular similarity: a key technique in molecular informatics. *Org Biomol Chem*. 2004; 2: 3204–18.
85. **Shoichet BK.** Virtual screening of chemical libraries. *Nature*. 2004; 432: 862–5.
86. **Klebe G.** Virtual ligand screening: strategies, perspectives and limitations. *Drug Discov Today*. 2006; 11: 580–94.
87. **Keiser MJ, Roth BL, Armbruster BN, et al.** Relating protein pharmacology by ligand chemistry. *Nat Biotechnol*. 2007; 25: 197–206.
88. **Mason JS, Good AC, Martin EJ.** 3-D pharmacophores in drug discovery. *Curr Pharm Des*. 2001; 7: 567–97.
89. **Lengauer T, Rarey M.** Computational methods for biomolecular docking. *Curr Opin Struct Biol*. 1996; 6: 402–6.
90. **Sharples D.** Factors affecting the binding of tricyclic tranquillizers and antidepressants to human serum albumin. *J Pharm Pharmacol*. 1976; 28: 100–5.
91. **Yeo LP, Geerts D, Mocz G, et al.** Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. *BMC Cancer*. 2015; 15: 477.
92. **Afzal AM, Mussa HY, Turner RE, et al.** A multi-label approach to target prediction taking ligand promiscuity into account. *J Cheminform*. 2015; 7: 24.
93. **Barneh F, Jafari M, Mirzaie M.** Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database. *Brief Bioinform*. 2015; 10.1093/bib/bbv094.
94. **Mukesh Bansal, Yang J, Karan C, et al.** A community computational challenge to predict the activity of pairs of compounds. *Nat Biotechnol*. 2014; 32: 1213–22.
95. **Hopkins AL.** Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol*. 2008; 4: 682–90.
96. **Gu J, Zhang X, Ma Y, et al.** Quantitative modeling of dose-response and drug combination based on pathway network. *J Cheminform*. 2015; 7: 19.
97. **Sun X, Vilar S, Tatonetti NP.** High-throughput methods for combinatorial drug discovery. *Sci Transl Med*. 2013; 5: 205rv1.
98. **Wagenlehner FM, Umeh O, Steenbergen J, et al.** Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet*. 2015; 385: 1949–56.
99. **Howman A, Chapman TL, Langdon MM, et al.** Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. *Lancet*. 2013; 381: 744–51.
100. **Blonde L, Jendle J, Gross J, et al.** Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. *Lancet*. 2015; 385: 2057–66.
101. **Smolen JS, Emery P, Fleischmann R, et al.** Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. *Lancet*. 2014; 383: 321–32.
102. **Burmester GR, Blanco R, Charles-Schoeman C, et al.** Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis

- factor inhibitors: a randomised phase 3 trial. *Lancet*. 2013; 381: 451–60.
103. **Stewart AK, Rajkumar SV, Dimopoulos MA, et al.** Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015; 372: 142–52.
  104. **Benboubker L, Dimopoulos MA, Dispenzieri A, et al.** Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014; 371: 906–17.
  105. **Mateos MV, Hernandez MT, Giraldo P, et al.** Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. *N Engl J Med*. 2013; 369: 438–47.
  106. **Simkens LH, van Tinteren H, May A, et al.** Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. *Lancet*. 2015; 385: 1843–52.
  107. **Loupakis F, Cremolini C, Masi G, et al.** Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med*. 2014; 371: 1609–18.
  108. **Sahoo RK, Kumar L.** Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. *N Engl J Med*. 2014; 370: 478–9.
  109. **Saltz LB, Bach PB.** Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. *N Engl J Med*. 2014; 370: 478.
  110. **Von Hoff DD, Goldstein D, Renschler MF.** Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. *N Engl J Med*. 2014; 370: 479–80.
  111. **Goede V, Fischer K, Busch R, et al.** Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*. 2014; 370: 1101–10.
  112. **Cunningham D, Hawkes EA, Jack A, et al.** Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet*. 2013; 381: 1817–26.
  113. **Swain SM, Baselga J, Kim SB, et al.** Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*. 2015; 372: 724–34.
  114. **Tolaney SM, Barry WT, Dang CT, et al.** Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. *N Engl J Med*. 2015; 372: 134–41.
  115. **Long GV, Stroyakovskiy D, Gogas H, et al.** Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*. 2015; 386: 444–51.
  116. **Long GV, Stroyakovskiy D, Gogas H, et al.** Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*. 2014; 371: 1877–88.
  117. **Larkin J, Chiarion-Sileni V, Gonzalez R, et al.** Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med*. 2015; 373: 23–34.
  118. **Wolchok JD, Kluger H, Callahan MK, et al.** Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med*. 2013; 369: 122–33.
  119. **Robert C, Karaszewska B, Schachter J, et al.** Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*. 2015; 372: 30–9.